Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 17/20 | 0.53 |
| ▸ | RXRB | P28702 | 2/20 | 0.53 |
| ▸ | RXRG | P48443 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3213511 | 0.96 | RXRA (0.53) | RXRARXRBRXRGPPARGHRH4 | |
| SCHEMBL3192272 | 0.92 | RXRA (0.43) | RXRARXRBRXRGPPARGTSHR | |
| SCHEMBL3216019 | 0.90 | RXRA (0.49) | RXRARXRBRXRGPPARG | |
| SCHEMBL3125823 | 0.89 | TSHR (0.52) | RXRARXRBRXRGPPARGTSHR | |
| SCHEMBL3125745 | 0.89 | RXRA (0.48) | RXRARXRBRXRGPPARG | |
| SCHEMBL3125660 | 0.88 | RXRA (0.42) | RXRARXRBRXRGPPARGTSHR | |
| SCHEMBL3215147 | 0.87 | TSHR (0.46) | RXRARXRBRXRGPPARGTSHR | |
| SCHEMBL3128439 | 0.85 | RXRA (0.55) | RXRARXRBRXRGPPARGTSHR | |
| SCHEMBL3218540 | 0.85 | RXRA (0.40) | RXRARXRBRXRGPPARGHRH4 | |
| SCHEMBL3214067 | 0.83 | MRGPRX4 (0.42) | RXRATSHRHRH4TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | RXRA 2856/4885RXRB 2676/4885RXRG 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.